Parallel session: Cascade of care towards elimination of viral hepatitis

 Viral hepatitis

Strauss 3
11 April 2019 16:00 - 18:00


PS-065 The global investment case for hepatitis C elimination
Margaret Hellard, Australia
11 April 2019 16:00 - 16:15

PS-066 Patient flow across physician specialties over the course of the hepatitis C care cascade: A real-world analysis from the United States
Nancy S Reau, United States
11 April 2019 16:15 - 16:30

PS-067 Increasing incidence of HCV-GT2 as well as reinfections within the ongoing epidemic of acute HCV infections among MSM in Central Europe
David Chromy, Austria
11 April 2019 16:30 - 16:45

PS-068 The hepatitis C cascade of care and treatment outcomes among people who inject drugs in a Norwegian low-threshold setting: A real life experience
Håvard Midgard, Norway
11 April 2019 16:45 - 17:00

PS-069 Towards HCV elimination: Feasibility of complete linkage to care by testing and treatment on the same day of screening: A pilot study
Gamal Shiha, Egypt
11 April 2019 17:00 - 17:15

PS-070 Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study
Heather Valerio, Australia
11 April 2019 17:15 - 17:30

PS-071 Piloting of integrated HCV, TB and HIV screening model at primary care level in Georgia
Irma Khonelidze, Georgia
11 April 2019 17:30 - 17:45

PS-072 Is homelessness the biggest hurdle to treatment success in the management of HCV in the era of direct acting antivirals? Results from the TraP HepC nationwide treatment initiative in Iceland
Magnús Gottfredsson, Iceland
11 April 2019 17:45 - 18:00